| GTO ID | GTC2895 |
| Trial ID |
NCT05197153
|
| Disease |
COVID-19
|
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Co-treatment | MVC-COV1901 |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II, Prospective, Randomized, Observer-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Heterologous Booster Dose With AZD1222, mRNA-1273, or MVC-COV1901 COVID-19 Vaccine in Adults |
| Year | 2022 |
| Country | China |
| Company sponsor | Medigen Vaccine Biologics Corp. |
| Other ID(s) | CT-COV-24 |